Atrium Therapeutics Inc.
RNA evidence brief
What we can confirm
- Market Cap:
- $194.1M
What it means
What to watch
Prepared research question
What matters most for RNA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · RNA
Atrium Therapeutics Inc. (RNA) is a biopharmaceutical company developing RNA therapeutics targeted to the heart for cardiomyopathies, with a lead candidate entering Phase 1/2 trials and a collaboration with Bristol Myers Squibb.
Key risk: Early-stage pipeline
Market Cap
$194.1M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Atrium Therapeutics Inc. (RNA) is a biopharmaceutical company developing RNA therapeutics targeted to the heart for cardiomyopathies, with a lead candidate entering Phase 1/2 trials and a collaboration with Bristol Myers Squibb.
- FDA cleared IND for ATR 1072, enabling the Corventis Phase 1/2 trial for PRKAG2 syndrome [sec · filed 2026-07-14]
- Cash and equivalents of $72.3M as of 2026-06-30 [sec]
- Total revenue of $3.0M and net income of -$20.2M for the period ending 2026-06-30 [sec]
- Shareholders' equity of $214.6M as of 2026-06-30 [sec]
- Collaboration with Bristol Myers Squibb (BMS) [news · published 2026-08-13]
What works
- FDA clearance of IND for ATR 1072 allows initiation of first Phase 1/2 clinical trial, a key milestone [sec · filed 2026-07-14]
- Preclinical data show ATR 1072 improved diastolic function and restored electrical conduction in mice, and was well tolerated in NHP studies [sec_mda · as of 2026-08-13]
- ATR 1086 demonstrated 100% survival and improved cardiac function in a humanized mouse model of PLN cardiomyopathy [sec_mda · as of 2026-08-13]
- Cash position of $263.9M (as of 2026-06-30) expected to fund operations for at least 12 months [sec_mda · as of 2026-08-13]
What to weigh
- Net loss of $20.2M for the period ending 2026-06-30 with only $3.0M in revenue [sec]
- Company is pre-revenue from product sales; all candidates are in early-stage development [sec_mda · as of 2026-08-13]
- Dependence on continued funding; cash runway is limited to about 12 months [sec_mda · as of 2026-08-13]
- Recent spin-off from Avidity (now part of Novartis) introduces execution risk in establishing independent operations [sec_mda · as of 2026-08-13]
From the filings
Quoted directly from source documents.
FDA cleared IND for ATR 1072 Phase 1/2 trial
“the U.S. Food and Drug Administration has cleared its Investigational New Drug ("IND") application allowing the Company to move forward with its CorventisTM Phase 1/2 clinical trial designed to evaluate ATR 1072 for the treatment of Protein Kinase AMP-activated non-catalytic subunit Gamma 2 ("PRKAG2") syndrome.”
SEC filings · July 14, 2026
Cash and equivalents of $263.9M as of June 30, 2026
“As of June 30, 2026, following the establishment of our independent cash management structure in connection with the Spin-Off, we held cash, cash equivalents, and short-term investments of $263.9 million.”
SEC MD&A · August 13, 2026
ATR 1086 showed 100% survival in PLN cardiomyopathy mouse model
“mATR 1086 treatment in this model resulted in 100% survival through the duration of the study for at least 20 weeks.”
SEC MD&A · August 13, 2026
Collaboration with Bristol Myers Squibb
“continued achievements under its collaboration with Bristol Myers Squibb (BMS).”
News · August 13, 2026
Risks & what to watch (4)›
Key risks
- Early-stage pipeline — All candidates are in preclinical or Phase 1/2; no approved products or revenue from sales [sec_mda · as of 2026-08-13]
- Cash runway limited — Cash expected to fund operations for at least 12 months; net loss of $20.2M in recent period [sec_mda · as of 2026-08-13]
- Spin-off integration risk — Recent separation from Avidity/Novartis may create operational and strategic uncertainties [sec_mda · as of 2026-08-13]
- Clinical trial execution — First Phase 1/2 trial (Corventis) just initiated; outcomes and timelines are uncertain [sec · filed 2026-07-14]
What to watch
- Initiation and early data from the Corventis Phase 1/2 trial for ATR 1072 [sec · filed 2026-07-14]
- Progress of ATR 1086 toward clinical development [sec_mda · as of 2026-08-13]
- Selection of next development candidate in 2027 [sec_mda · as of 2026-08-13]
- Updates on collaboration with Bristol Myers Squibb [news · published 2026-08-13]
Sources: News · SEC filings · SEC MD&A · Generated October 2, 2026 · How we verify sources →
Run Atrium Therapeutics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Atrium Therapeutics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
160
Total value held
$175.7M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 1,205,291 | $16.1M |
| ra capital management, l.p. | 864,102 | $11.6M |
| vanguard capital management llc | 626,869 | $8.4M |
| tig advisors, llc | 607,552 | $8.1M |
| pentwater capital management lp | 602,649 | $8.1M |
| o'connor alternative investments llc | 578,011 | $7.7M |
| sessa capital im, l.p. | 551,391 | $7.4M |
| goldman sachs group inc | 349,950 | $4.7M |
| farallon capital management llc | 349,360 | $4.7M |
| vanguard portfolio management llc | 344,369 | $4.6M |
Showing top 10 of 160 institutional holders of Atrium Therapeutics Inc.. Open the full 13F history after sign-in.
Short Interest
as of Mar 2, 2026- % of float
- 6.6%
- Days to cover
- 5.1
- Shares short
- 10,156,722
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
RNA short interestFrequently asked questions
What is the AI investment thesis for Atrium Therapeutics Inc.?
Atrium Therapeutics Inc. (RNA) is a biopharmaceutical company developing RNA therapeutics targeted to the heart for cardiomyopathies, with a lead candidate entering Phase 1/2 trials and a collaboration with Bristol Myers Squibb.
Who is the CEO of Atrium Therapeutics Inc.?
Ms. Kathleen P. Gallagher is the chief executive officer of Atrium Therapeutics Inc. (RNA).
Where is Atrium Therapeutics Inc. headquartered?
Atrium Therapeutics Inc. (RNA) is headquartered in San Diego, CA, United States.
What therapeutic areas does Atrium Therapeutics Inc. focus on?
Atrium Therapeutics Inc. develops therapies across Neurology, Cardiovascular.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.